Immunovant (IMVT) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunovant (IMVT) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 98.9% versus a loss of 4.3%. Over five years, IMVT leads with a +267.4% price change compared with -16.0% for QGEN. Qiagen N.V. is the larger company by market cap ($9.17 billion vs $6.49 billion), about 1.4 times the size.
Qiagen N.V. pays a dividend yielding 0.82%, while Immunovant does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | QGEN |
|---|---|---|
| Share price | $31.44 | $44.39 |
| Market cap | $6.49B | $9.17B |
| 1-day change | -1.89% | -0.91% |
| YTD return | +26.04% | -0.40% |
| 1-year return | +98.88% | -4.29% |
| 5-year return | +267.43% | -15.95% |
| P/E ratio (TTM) | — | 22.53 |
| Forward P/E | — | 16.99 |
| EPS (TTM) | $-2.82 | $1.97 |
| Dividend yield | 0.00% | 0.82% |
| Annual dividend | $0.00 | $0.363 |
| Revenue (latest FY) | — | $2.09B |
| Revenue growth (YoY) | — | +5.65% |
| Net income (latest FY) | $-505.61M | $424.88M |
| Gross margin | — | 62.18% |
| Operating margin | — | 22.29% |
| Net margin | — | 20.33% |
| 52-week high | $45.42 | $57.82 |
| 52-week low | $16.08 | $32.53 |
| Distance from 52-week high | -30.79% | -23.22% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +55.50% | +6.48% |
| Average volume | 1.22M | 2.75M |
| Shares outstanding | 206.55M | 206.50M |
| Employees | 315 | 5,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMVT has outperformed QGEN by 103.2 percentage points over the past year.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
IMVT vs QGEN FAQ
Which is bigger, Immunovant or Qiagen N.V.?
Qiagen N.V. (QGEN) is larger, with a market capitalization of $9.17B compared with $6.49B for Immunovant (IMVT).
Which stock has performed better over the past year, IMVT or QGEN?
IMVT returned +98.88% over the past 12 months, compared with -4.29% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Immunovant or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.82%, while Immunovant does not currently pay a regular dividend.
Are Immunovant and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.